Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets MicroRNA-146a and the toll-like receptor signaling pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 8, 2012, Pages 1856-1864

  Zhang, Li ^a   Chopp, Michael ^a,b   Liu, Xianshuang ^a   Teng, Hua ^a   Tang, Tao ^a   Kassis, Haifa ^a   Zhang, Zheng Gang ^a  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

endothelium; ischemia; microRNA; thrombolysis; toll like receptors

Indexed keywords

BORTEZOMIB; FIBRIN; FIBRINOGEN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ACTIVATED KINASE 1; MICRORNA 146A; PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN BLOOD VESSEL; BRAIN EMBOLISM; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ISOLATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; MALE; MONOTHERAPY; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE; TREATMENT OUTCOME; UPREGULATION;

AGING; ANIMALS; BORONIC ACIDS; CELLS, CULTURED; DOWN-REGULATION; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICRORNAS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PYRAZINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOLL-LIKE RECEPTORS;

EID: 84864280520     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.252619     Document Type: Article

References (40)

1. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397. (Pubitemid 27334820)
2. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680. (Pubitemid 32747155)
3. Constantin D, Cordenier A, Robinson K, Ala'Aldeen DA, Murphy S. Neisseria meningitidis-induced death of cerebrovascular endothelium: mechanisms triggering transcriptional activation of inducible nitric oxide synthase. J Neurochem. 2004;89:1166-1174. (Pubitemid 38715834)
4. Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci. 2005;25:1788-1796. (Pubitemid 40279284)
5. Singh AK, Jiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology. 2004;201:197-207. (Pubitemid 39023946)
6. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Röhr C, Prinz V, König J, Lehrach H, Nietfeld W, Trendelenburg G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun. 2007;359:574-579. (Pubitemid 46898990)
7. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun. 2007;353:509-514. (Pubitemid 46023466)
8. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Krueger C, Nitsch R, Meisel A, Weber Jr. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol. 2007;190:28-33. (Pubitemid 47625604)
9. Nagyoszi P, Wilhelm I, Farkas AE, Fazakas C, Dung NT, Haskó J, Krizbai IA. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int. 2010;57:556-564.
10. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007;115:1599-1608. (Pubitemid 46648645)
11. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, Mattson MP. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA. 2007;104:13798-13803. (Pubitemid 350003400)
12. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9:6316-6325. (Pubitemid 38031815)
13. Henninger N, Sicard KM, Bouley J, Fisher M, Stagliano NE. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett. 2006;398:300-305. (Pubitemid 43673703)
14. Zhang L, Zhang ZG, Buller B, Jiang J, Jiang Y, Zhao D, Liu X, Morris D, Chopp M. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia. Stroke. 2010;41:1001-1007.
15. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grünebach F, Brossart P. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood. 2006;108:551-558. (Pubitemid 44061355)
16. Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P, Paraskeva A, Bougiouklis D, Palladas P, Yiangou M, Anagnostopoulos A. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum. 2010;62:3277-3288.
17. Fischer S, Nishio M, Peters SC, Tschernatsch M, Walberer M, Weidemann S, Heidenreich R, Couraud PO, Weksler BB, Romero IA, Gerriets T, Preissner KT. Signaling mechanism of extrACEllular RNA in endothelial cells. FASEB J. 2009;23:2100-2109.
18. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing Jr. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92. (Pubitemid 27431437)
19. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011. (Pubitemid 32285175)
20. Kaltschmidt C, Kaltschmidt B, Henkel T, Stockinger H, Baeuerle PA. Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody. Biol Chem Hoppe-Seyler. 1995;376:9-16.
21. Liu XS, Zhang ZG, Zhang L, Morris DC, Kapke A, Lu M, Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab. 2006;26:787-796.
22. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008;9:684-691. (Pubitemid 351712639)
23. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001;167:2887-2894. (Pubitemid 32768923)
24. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481-12486. (Pubitemid 44267285)
25. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci USA. 1997;94:12829-12832. (Pubitemid 27518436)
26. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol. 2001;116:637-646. (Pubitemid 34453203)
27. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, Kalbfleisch JH, Browder IW, Li C. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol. 2008;199:75-82.
28. Dawson DA, Furuya K, Gotoh J, Nakao Y, Hallenbeck JM. Cerebrovascular hemodynamics and ischemic tolerance: lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab. 1999;19:616-623. (Pubitemid 30161213)
29. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
30. Karikó K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab. 2004;24:1288-1304. (Pubitemid 39482492)
31. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-2704. (Pubitemid 38737913)
32. Ryu JK, Davalos D, Akassoglou K. Fibrinogen signal transduction in the nervous system. J Thromb Haemost. 2009;7 Suppl 1:151-154.
33. Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol. 2009;183:2150-2158.
34. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, Sun G, Tay J, Linsley PS, Baltimore D. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208:1189-1201.
35. Boldin MP, Baltimore D. MicroRNAs, new effectors and regulators of NF-κB. Immunol Rev. 2012;246:205-220.
36. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228-234.
37. Izzi L, Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene. 2004;23:2071-2078. (Pubitemid 38496736)
38. Lo RS, Massagué J. Ubiquitin-dependent degradation of TGF-beta-activated smad2. Nat Cell Biol. 1999;1:472-478.
39. Boominathan L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS ONE. 2010;5:e10615.
40. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454:56-61. (Pubitemid 351931982)